Journal of Medicinal Chemistry p. 5471 - 5487 (2016)
Update date:2022-08-15
Topics:
Prado, Verónica
Lence, Emilio
Maneiro, María
Vázquez-Ucha, Juan C.
Beceiro, Alejandro
Thompson, Paul
Hawkins, Alastair R.
González-Bello, Concepción
The large conformational changes observed by Molecular Dynamics simulation studies on the product release in the LID and shikimic acid binding (SB) domains of the shikimate kinase (SK) enzyme have been exploited in the development of reversible competitive inhibitors against SK from Mycobacterium tuberculosis and Helicobacter pylori. This enzyme is a recognized target for antibiotic drug discovery. The reported C5-substituted shikimic acid analogues interact with the dynamic apolar pocket that surrounds the C4 and C5 hydroxyl groups of the natural substrate, cause the opening of the LID and SB domains, and capture the essential arginine far from the ATP binding site as required for catalysis. The 3-nitrobenzyl 3e and 5-benzothiophenyl derivatives 3i proved to be the most potent inhibitors. An ester prodrug of 3i was the most efficient derivative in achieving good in vitro activity against H. pylori, having a MIC value of 4 μg/mL.
View MoreShanghai Xinda Pharmaceuticals Co., Ltd.
Contact:86-21-33692333-8008
Address:999 Linxian Road, Jinshan Industrial Park, Shanghai, China
Contact:0086-29-89196322
Address:North of the Fifth Keji Road, Hi-Tech Industrial Zone, Xi'an City, Shaanxi Province, China
Jiangsu Chiatai Qingjiang Pharmaceutical Co.,Ltd
Contact:+86-517-86283327
Address:9 North Hantai Road, Huaian, China
Contact:+86-310-7092106
Address:Quzhou Modern & New Industrial Park, Handan, Hebei 057250, China
Jiangsu Fengshan Group Co., Ltd.
Contact:86-25-86558671
Address:1903,Central International Mansion 105-6 North Zhongshan Road, Nanjing, China
Doi:10.1016/j.tetlet.2011.10.133
(2012)Doi:10.1021/om2011529
(2012)Doi:10.1039/c6ob02612e
(2017)Doi:10.1002/hlca.19910740320
(1991)Doi:10.1039/c1ob06571h
(2012)Doi:10.1021/jo2022789
(2012)